Nicole Hachmann

Nicole Hachmann

Auto-generated profile, based on publicly available information

Nicole Hachmann

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NHNicole P. Hachmann
Nicole P. Hachmann
JMJessica Miller
Jessica Miller
ACAi-Ris Y. Collier
Ai-Ris Y. Collier
JVJohn D. Ventura
John D. Ventura
JYJingyou Yu
Jingyou Yu
DBDan H. Barouch
Dan H. Barouch
In recent months, multiple lineages of the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged,1 with subvariants BA.1 and BA.2 showing substantial escape from neutralizing antibodies.2-5 Subvariant BA.2.12.1 is now the dominant strain in the United States, and BA.4 and BA.5 are dominant in South Africa ( Figure 1A ). Subvariants BA.4 and BA.5 have identical sequences of the spike protein.

9 February 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
ACAi-Ris Y. Collier
Ai-Ris Y. Collier
JMJessica Miller
Jessica Miller
NHNicole P. Hachmann
Nicole P. Hachmann
KMKatherine McMahan
Katherine McMahan
JLJinyan Liu
Jinyan Liu
DBDan H. Barouch
Dan H. Barouch

16 February 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
JMJessica Miller
Jessica Miller
NHNicole P. Hachmann
Nicole P. Hachmann
ACAi-Ris Y. Collier
Ai-Ris Y. Collier
NLNinaad Lasrado
Ninaad Lasrado
CMCamille R. Mazurek
Camille R. Mazurek
DBDan H. Barouch
Dan H. Barouch

25 November 2022 in Science Immunology
Verified
Journal Article
Open access
JLJinyan Liu
Jinyan Liu
JYJINGYOU YU
JINGYOU YU
KMKatherine McMahan
Katherine McMahan
CJCatherine Jacob-Dolan
Catherine Jacob-Dolan
XHXuan He
Xuan He
DBDan H. Barouch
Dan H. Barouch
Spike-specific neutralizing antibodies (NAbs) are generally considered key correlates of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recently, robust vaccine prevention of severe disease with SARS-CoV-2 variants that largely escape NAb responses has been reported, suggesting a role for other immune parameters for virologic control. However, direct data demonstrating a role of CD8 + T cells in vaccine protection have not yet been reported. In this study, we show that vaccine-elicited CD8 + T cells contribute substantially to virologic control after SARS-CoV-2 challenge in rhesus macaques. We vaccinated 30 macaques with a single immunization of the adenovirus vector–based vaccine Ad26.COV2.S or sham and then challenged them with 5 × 10 5 median tissue culture infectious dose SARS-CoV-2 B.1.617.2 (Delta) by the intranasal and intratracheal routes. All vaccinated animals were infected by this high-dose challenge but showed rapid virologic control in nasal swabs and bronchoalveolar lavage by day 4 after challenge. However, administration of an anti-CD8α– or anti-CD8β–depleting monoclonal antibody in vaccinated animals before SARS-CoV-2 challenge resulted in higher levels of peak and day 4 virus in both the upper and lower respiratory tracts. These data demonstrate that CD8 + T cells contribute substantially to vaccine protection against SARS-CoV-2 replication in macaques.

14 December 2023 in Nature
Verified
Journal Article
Open access
PDF file
KMKatherine McMahan
Katherine McMahan
FWFrank Wegmann
Frank Wegmann
MAMalika Aid
Malika Aid
MSMichaela Sciacca
Michaela Sciacca
JLJinyan Liu
Jinyan Liu
DBDan H. Barouch
Dan H. Barouch
A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with current Omicron subvariants1,2, although they still provide protection against severe disease. Enhanced mucosal immunity may be required to block infection and onward transmission. Intranasal administration of current vaccines has proven inconsistent3–7, suggesting that alternative immunization strategies may be required. Here we show that intratracheal boosting with a bivalent Ad26-based SARS-CoV-2 vaccine results in substantial induction of mucosal humoral and cellular immunity and near-complete protection against SARS-CoV-2 BQ.1.1 challenge. A total of 40 previously immunized rhesus macaques were boosted with a bivalent Ad26 vaccine by the intramuscular, intranasal and intratracheal routes, or with a bivalent mRNA vaccine by the intranasal route. Ad26 boosting by the intratracheal route led to a substantial expansion of mucosal neutralizing antibodies, IgG and IgA binding antibodies, and CD8+ and CD4+ T cell responses, which exceeded those induced by Ad26 boosting by the intramuscular and intranasal routes. Intratracheal Ad26 boosting also led to robust upregulation of cytokine, natural killer, and T and B cell pathways in the lungs. After challenge with a high dose of SARS-CoV-2 BQ.1.1, intratracheal Ad26 boosting provided near-complete protection, whereas the other boosting strategies proved less effective. Protective efficacy correlated best with mucosal humoral and cellular immune responses. These data demonstrate that these immunization strategies induce robust mucosal immunity, suggesting the feasibility of developing vaccines that block respiratory viral infections.

23 October 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
NLNinaad Lasrado
Ninaad Lasrado
MRMarjorie Rowe
Marjorie Rowe
KMKatherine McMahan
Katherine McMahan
NHNicole P. Hachmann
Nicole P. Hachmann
JMJessica Miller
Jessica Miller
DBDan H. Barouch
Dan H. Barouch
Current COVID-19 vaccines provide robust protection against severe disease but minimal protection against acquisition of infection. Intramuscularly administered COVID-19 vaccines induce robust serum neutralizing antibodies (NAbs), but their ability to boost mucosal immune responses remains to be determined. In this study, we show that the XBB.1.5 messenger RNA (mRNA) boosters result in increased serum neutralization to multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in humans, including the dominant circulating variant JN.1. In contrast, we found that the XBB.1.5 mRNA booster did not augment mucosal NAbs or mucosal IgA responses, although acute SARS-CoV-2 XBB infection substantially increased mucosal antibody responses. These data demonstrate that current XBB.1.5 mRNA boosters substantially enhance peripheral antibody responses but do not robustly increase mucosal antibody responses. Our data highlight a separation between the peripheral and mucosal immune systems in humans and emphasize the importance of developing next-generation vaccines to augment mucosal immunity to protect against respiratory virus infections.